drugset / Trial / NCT00136903

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

NCT00136903

Phase 2 Completed 32 enrolled Mesoblast, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

To establish the safety and efficacy of two dose levels of ex-vivo cultured adult human mesenchymal stem cells (hMSCs) (Prochymal®) in participants experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC) transplant.

Timeline

Start
2005-04-27
Primary completion
2006-07-28
Completion
2008-07-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prochymal® Cell therapy 2e+06 cells/kg Intravenous
Comparator Prochymal® Cell therapy 8e+06 cells/kg Intravenous
Comparator Cyclosporine Peptide
Comparator Methylprednisolone Other / unclassified 2 mg/kg Intravenous
Comparator Mycophenolate Mofetil Small molecule
Comparator Prednisone Other / unclassified 2.5 mg/kg Oral
Comparator Tacrolimus Small molecule